Clinical trials: Metastatic Solid Tumor Cancer
Solid Tumors Harboring MET Amplification
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan.
- Trial name
- NCT07196644
- Testing
- Telisotuzumab Adizutecan
- Where
- 38 sites in United States, Israel and 3 more
- Volunteers
- 100 people
- Sponsor
- AbbVie
Solid Tumors, Glioblastoma
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
This is an open-label, multi-center, sequential groups, dose-escalation study of CBL0137 administered intravenously in participants with metastatic or unresectable advanced solid malignancies.
- Trial name
- NCT01905228
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incuron
Solid Tumor, Ewing Sarcoma
Expanded Access of Vigil in Solid Tumors
This is an expanded access study involving an investigational product named Vigil. Vigil is considered immunotherapy. Patients who participated in another clinical trial sponsored by Gradalis, and had Vigil made from their tumor…
- Conditions
- Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT03842865
- Testing
- Vigil
- Where
- United States
- Sponsor
- Gradalis, Inc.
Neoplasms, Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors.
- Conditions
- Neoplasms, Solid Tumors, Metastases
- Trial name
- NCT00569036
- Testing
- BMS-754807
- Where
- 5 sites in Australia
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.
- Conditions
- Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
- Trial name
- NCT04805307
- Testing
- CMG901
- Where
- 32 sites in China
- Volunteers
- 176 people
- Sponsor
- Keymed Biosciences Co.Ltd
Solid Tumor
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS…
- Trial name
- NCT06166836
- Testing
- D1553, IN10018（Ifebemtinib）
- Where
- 10 sites in China
- Volunteers
- 140 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Advanced Non-small Cell Lung Cancer
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase).
- Trial name
- NCT02108964
- Testing
- EGF816
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Solid Tumor, Solid Tumor
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
- Conditions
- Malignant Solid Tumor, Solid Tumor, Metastatic Tumor
- Trial name
- NCT01648764
- Testing
- LY2334737
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
- Trial name
- NCT07857616
- Testing
- SI-B036
- Where
- 7 sites in United States
- Volunteers
- 424 people
- Sponsor
- SystImmune Inc.
Tumors, Hematologic Malignancies
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally…
- Trial name
- NCT01375842
- Testing
- Atezolizumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 661 people
- Sponsor
- Genentech, Inc.
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA.
- Trial name
- NCT06493552
- Testing
- SEphB4-HSA, Pembrolizumab, Gemcitabine
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Vasgene Therapeutics, Inc
Solid Tumors, Advanced Solid Tumors
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
- Conditions
- Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT06873789
- Testing
- INCB177054, Retifanlimab
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
Recurrent or Metastatic Solid Tumors
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.
- Trial name
- NCT07015697
- Testing
- Trastuzumab Deruxtecan
- Where
- 31 sites in United States, Brazil and 5 more
- Volunteers
- 76 people
- Sponsor
- Daiichi Sankyo
Breast Cancer, Breast Cancer Metastatic
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.
- Conditions
- Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INX-315-01 (NCT05735080)
- Testing
- INX-315, Fulvestrant, Abemaciclib
- Where
- 18 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Incyclix Bio
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
The purpose of this First-in-Human, Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of MC001 in adults with advanced or…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
- Trial name
- NCT07909356
- Testing
- MC001
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medicovestor, Inc
Metastatic Tumor, Advanced Solid Tumor
A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T
As a phase I clinical research，this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05468190
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.